Fenofibrate is a specific agonist of PPARα, and is characterized by relatively low systemic toxicity. Recent studies have revealed that fenofibrate suppresses the growth of several cancer lines in vitro, but the exact relation between fenofibrate and irradiation has not been explored. The purpose of this study was to investigate the radiosensitivity enhancement effects of fenofibrate combined with radiation on the human esophageal carcinoma cell lines Eca-109 and TE1, and the potential mechanism underlying these effects.
Methods and Study design
The Eca-109 and TE1 cell lines were tested by the CCK-8 assay for cell proliferation. The multitarget click model was used to delineate the survival curve and radiosensitivity was determined after cells were treated with fenofibrate and/or x-ray radiation. Flow cytometry was used to examine the effect of fenofibrate and radiation on the cell cycle. The expression of vascular endothelial growth factor (VEGF) protein was detected by Western blot analysis.
Results
When given alone, fenofibrate had a time- and concentration-dependent cytotoxic effect on cells. The dose-enhancement ratio for combined fenofibrate and radiation increased markedly compared with fenofibrate alone. Further, the ratio of cells in the G2/M phase after fenofibrate and radiation was higher than that after fenofibrate or irradiation alone. The expression of VEGF protein was suppressed after treatment with fenofibrate alone or fenofibrate plus radiation.
Conclusions
Fenofibrate can enhance the radiosensitivity of human esophageal carcinoma cells by increasing G2/M phase arrest. Modulation of VEGF expression could contribute in vivo to a favorable interaction.
ParkinD.M., BrayF., FerlayJ., PisaniP.Global cancer statistics, 2002. CA Cancer J Clin.2005; 55(2): 74–108.
2.
YangL., LiL.D., ChenY.D., ParkinD.M.Cancer incidence and mortality estimates and prediction for year 2000 and 2005 in China. Chinese Journal of Health Statistics.2005; 22(4): 218–221.
3.
MarietteC., PiessenG., TribouletJ.P.Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol.2007; 8(6): 545–553.
4.
KandazM., ErtekinM.V., BiliciM.Retrospective analysis of patients with esophageal cancer treated with radiotherapy and/or chemoradiotherapy. Tumori.2012; 98(4): 445–450.
5.
SchenaM., La RovereE., SolerioD.. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a mono-centric study. Tumori.2012; 98(4): 451–457.
6.
MinskyB.D., PajakT.F., GinsbergR.J.. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol.2002; 20(5): 1167–1174.
7.
StahlM., StuschkeM., LehmannN.. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol.2005; 23(10): 2310–2317.
8.
KvolsL.K.Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets. J Nucl Med.2005; 46(Suppl 1): 187S–190S.
9.
EscherP., WahliW.Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res.2000; 448(2): 121–138.
10.
Pineda TorraI., GervoisP., StaelsB.Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol.1999; 10(2): 151–159.
GrabackaM., PlachaW., PlonkaP.M.. Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res.2004; 296(2): 54–58.
14.
GrabackaM., PlonkaP.M., UrbanskaK., ReissK.Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res.2006; 12(10): 3028–3036.
15.
CollettG.P., BettsA.M., JohnsonM.I.. Peroxisome proliferator-activated receptor α is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res.2000; 6(8): 3241–3248.
16.
SuchanekK.M., MayF.J., RobinsonJ.A.. Peroxisome proliferator-activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog.2002; 34(4): 165–171.
17.
TanakaT., KohnoH., YoshitaniS.. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res.2001; 61(6): 2424–2428.
18.
MaggioraM., BolognaM., CerùM.P.. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int J Cancer.2004; 112(6): 909–919.
19.
SaidiS.A., HollandC.M., Charnock-JonesD.S., SmithS.K.In vitro and in vivo effects of the PPAR-α agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer.2006; 5(1): 13.
ZhouJ., ZhangS., XueJ.. Activation of peroxisome proliferator-activated receptor α (PPARα) suppresses hypoxia-inducible factor-1α (HIF-1α) signaling in cancer cells. J Biol Chem.2012; 287(42): 35161–35169.
22.
SohdaM., IshikawaH., MasudaN.. Pretreatment evaluation of combined HIF-1α, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer.2004; 110(6): 838–844.
23.
HovingaK.E., StalpersL.J., van BreeC.. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines—a clue to radioresistance?J Neurooncol.2005; 74(2): 99–103.
24.
YuJ., LiuF., SunM., SunZ., SunS.Enhancement of radiosensitivity and the potential mechanism on human esophageal carcinoma cells by tetrandrine. Cancer Biother Radiopharm.2011; 26(4): 437–442.
25.
YuJ., LiuF., SunZ., SunM., SunS.The enhancement of radiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism. Cancer Biother Radiopharm.2011; 26(2): 219–227.
26.
ClemonsN.J., ShannonN.B., AbeyratneL.R.. Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma. Carcinogenesis.2010; 31(9): 1669–1675.
27.
WilkA., UrbanskaK., GrabackaM.. Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro.Cell Cycle.2012; 11(14): 2660–2671.
28.
YamasakiD., KawabeN., NakamuraH.. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms. Eur J Cell Biol.2011; 90(8): 657–664.
29.
ZhaoH., ZhuC., QinC.. Fenofibrate down-regulates the expressions of androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate cancer cell line LNCaP. Biochem Biophys Res Commun.2013; 432(2): 320–325.
30.
HuX., XingL., WeiX.. Nonangiogenic function of VEGF and enhanced radiosensitivity of HeLa cells by inhibition of VEGF expression. Oncol Res.2012; 20(2-3): 93–101.
31.
LiW.F., ZhangL., LiH.Y., ZhengS.S., ZhaoL.WISP-1 contributes to fractionated irradiation-induced radioresistance in esophageal carcinoma cell lines and mice. PLoS ONE.2014; 9(4): e94751.
32.
HuangM., MiaoZ.H., ZhuH., CaiY.J., LuW., DingJ.Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther.2008; 7(6): 1440–1449.
33.
MoragodaL., JaszewskiR., MajumdarA.P.Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res.2001; 21(2A): 873–878.
34.
LiuE., WuJ., CaoW.. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol.2007; 85(3): 263–270.
35.
HuangS.M., HarariP.M.Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res.2000; 6(6): 2166–2174.
